-
Mashup Score: 0
In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
In the Phase 2 ARCHER trial, ANX007 protected against visual acuity loss and remained well-tolerated for patients with geographic atrophy.
At #AAO2024: ANX007, a selective inhibitor of C1q, demonstrated consistent protection against visual acuity loss in #GeographicAtrophy in the Phase 2 ARCHER trial. Read more: https://t.co/5HutQIaFWh https://t.co/HQbqkMcIKU